|
Other anticoagulants
Citations 31-40 of 93 total displayed.
|
Past content
(since Jan 2001):
|
- Articles
Randomized, Double-Blind, Dose-Ranging Study of Otamixaban, a Novel, Parenteral, Short-Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention. The SEPIA-PCI Trial
- Marc Cohen, Deepak L. Bhatt, John H. Alexander, Gilles Montalescot, Christoph Bode, Timothy Henry, Jean-Francois Tamby, Jan Saaiman, Stanislas Simek, Johannes De Swart on behalf of the SEPIA-PCI Trial Investigators
Circulation published May 14, 2007, doi:10.1161/CIRCULATIONAHA.106.653428
[Abstract]
- Vascular Medicine
First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer Technology: A Phase 1a Pharmacodynamic Evaluation of a Drug-Antidote Pair for the Controlled Regulation of Factor IXa Activity
- Christopher K. Dyke, Steven R. Steinhubl, Neal S. Kleiman, Richard O. Cannon, Laura G. Aberle, Min Lin, Shelley K. Myles, Chiara Melloni, Robert A. Harrington, John H. Alexander, Richard C. Becker, and Christopher P. Rusconi
Circulation 2006;114:2490-2497; published online before print as doi:10.1161/CIRCULATIONAHA.106.668434
[Abstract]
[Full text]
- Editorials
The Scientific Community’s Quest to Identify Optimal Targets for Anticoagulant Pharmacotherapy
- Kenneth W. Mahaffey and Richard C. Becker
Circulation 2006;114:2313-2316, doi:10.1161/CIRCULATIONAHA.106.664169
[Full text]
- Preventive Cardiology
A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement
- Bengt I. Eriksson, Lars C. Borris, Ola E. Dahl, Sylvia Haas, Menno V. Huisman, Ajay K. Kakkar, Eva Muehlhofer, Christoph Dierig, Frank Misselwitz, Peter Kälebo for the ODIXa-HIP Study Investigators
Circulation 2006;114:2374-2381; published online before print as doi:10.1161/CIRCULATIONAHA.106.642074
[Abstract]
[Full text]
- Articles
A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement
- Bengt I. Eriksson, Lars C. Borris, Ola E. Dahl, Sylvia Haas, Menno V. Huisman, Ajay K. Kakkar, Eva Muehlhofer, Christoph Dierig, Frank Misselwitz, Peter Kälebo for the ODIXa-HIP Study Investigators
Circulation published November 20, 2006, doi:10.1161/CIRCULATIONAHA.106.642074
[Abstract]
- Articles
First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer Technology. A Phase 1a Pharmacodynamic Evaluation of a Drug-Antidote Pair for the Controlled Regulation of Factor IXa Activity
- Christopher K. Dyke, Steven R. Steinhubl, Neal S. Kleiman, Richard O. Cannon, Laura G. Aberle, Min Lin, Shelley K. Myles, Chiara Melloni, Robert A. Harrington, John H. Alexander, Richard C. Becker, and Christopher P. Rusconi
Circulation published November 13, 2006, doi:10.1161/CIRCULATIONAHA.106.668434
[Abstract]
- Editorials
Glycoprotein IIb/IIIa Inhibitors in the Elderly: Fear of Age or Age of Fear?
- Gilles Montalescot
Circulation 2006;114:2004-2006, doi:10.1161/CIRCULATIONAHA.106.658245
[Full text]
- Images in Cardiovascular Medicine
The Case of a Disappearing Left Atrial Appendage Thrombus: Direct Visualization of Left Atrial Thrombus Migration, Captured by Echocardiography, in a Patient With Atrial Fibrillation, Resulting in a Stroke
- Amit Parekh, Radhika Jaladi, Sushant Sharma, William A. Van Decker, and Michael D. Ezekowitz
Circulation 2006;114:e513-514e, doi:10.1161/CIRCULATIONAHA.106.617886
[Full text]
- Cardiology Patient Pages
Heparin-Induced Thrombocytopenia
- Steven A. Baroletti and Samuel Z. Goldhaber
Circulation 2006;114:e355-356e, doi:10.1161/CIRCULATIONAHA.106.632653
[Full text]
- Corrections
Correction
-
Circulation 2006;113:e695, doi:10.1161/CIRCULATIONAHA.106.174785
[Full text]
|
|
